101.418-12/04 – including *Taq* pol., IFU-01 **101.418-12**u/**04** – without *Taq* pol., IFU-02

Visit <u>www.olerup-ssp.com</u> for "Instructions for Use" (IFU)

Lot No.: 10S

Lot-specific information

CERTIFICATE OF ANALYSIS

Olerup SSP® HLA-A*68 SSP

Product number: 101.418-12/04 – including *Tag* pol.

101.418-12u/04u - without Tag pol.

Lot number: 10S

Expiry date: 2015-October-01

Number of tests: 12 tests – Product No. 101.418-12/12u

4 tests - Product No. 101.418-04/04u

Number of wells per test: 46

Well specifications:

Well No.	Production No.	Well No.	Production No.	Well No.	Production No.
1	2012-975-01	17	2012-975-17	33	2012-975-33
2	2012-975-02	18	2012-975-18	34	2012-975-34
3	2012-975-03	19	2012-975-19	35	2012-975-35
4	2012-975-04	20	2012-975-20	36	2013-160-36
5	2012-975-05	21	2012-975-21	37	2012-975-37
6	2012-975-06	22	2012-975-22	38	2012-975-38
7	2012-975-07	23	2012-975-23	39	2012-975-39
8	2012-975-08	24	2012-975-24	40	2012-975-40
9	2012-975-09	25	2013-160-25	41	2012-975-41
10	2012-975-10	26	2012-975-26	42	2012-975-42
11	2012-975-11	27	2012-975-27	43	2013-160-43
12	2012-975-12	28	2012-975-28	44	2013-160-44
13	2012-975-13	29	2013-160-29	45	2013-160-45
14	2013-160-14	30	2013-160-30	46	2013-160-46
15	2012-975-15	31	2012-975-31		
16	2012-975-16	32	2013-160-32	1	

The specificity of each primer solution of the kit has been tested against 48 well characterized IHWC cell line DNAs.

No DNAs carrying the alleles to be amplified by primer solutions 5, 7 to 9, 11 to 13, 15, 16, 19 to 21, 25 to 28, 32 to 35 and 37 to 46 were available. The specificities of the primers in primer solutions 5, 7 to 9, 11, 13, 15, 16, 20, 21, 25 to 27, 37 and 41 were tested by separately adding additional 5'-primers, respectively additional 3'-primers. The specificities of the 3'-primers in primer solutions 12, 19, 28, 34, 39, 42 and 46 were tested by separately adding one additional 5'-primer, it was not possible test the 5'-primers. In primer solutions 14, 32, 33, 35, 38, 40 and 43 to 45 it was only possible to test the 5'-primers, the 3'-primers were not possible to test. In primer solution 5, 7, 8, 11, 17 and 27 one of the 5'-primers was not possible to test. In primer solutions 8, 9, 15 to 16, 18, 21, 26 and 27 one or two of the 3'-primers were not possible to test. Additional primers in primer solutions 4, 6 and 29 were tested tested by separately adding either one additional 5'-primer, or one additional 3'-primer.

101.418-12/04 – including *Taq* **pol.,** IFU-01 **101.418-12u/04– without** *Taq* **pol.,** IFU-02

Visit <u>www.olerup-ssp.com</u> for "Instructions for Use" (IFU)

Lot No.: 10S

Lot-specific information

Results:

No false positive or false negative amplifications were obtained.

Date of approval: 2013-May-30

Approved by:

Production Quality Control

Kurin clatteston

101.418-12/04 – including *Taq* pol., IFU-01 **101.418-12u/04** – without *Taq* pol., IFU-02

Visit <u>www.olerup-ssp.com</u> for "Instructions for Use" (IFU)

Lot No.: 10S

Lot-specific information

Declaration of Conformity

Product name:

Olerup SSP[®] HLA-A*68 101.418-12/12u, 04/04u

Product number: Lot number:

10S

Intended use:

HLA-A*68 high resolution histocompatibility testing

Manufacturer:

Olerup SSP AB Franzengatan 5

SE-112 51 Stockholm, Sweden

Phone: +46-8-717 88 27 **Fax:** +46-8-717 88 18

We, *Olerup* SSP AB, hereby declare that this product, to which this Declaration of Conformity relates is in conformity with the following Standard(s) and other normative document(s) ISO 9001:2008 and ISO 13485:2012, following the provisions of the 98/79/EC Directive on *in vitro* diagnostic medical devices, Annex II List B, as transposed into the national laws of the Member States of the European Union.

The Technical Documentation File is maintained at *Olerup* SSP AB, Franzengatan 5, SE-112 51 Stockholm, Sweden.

Notified Body: Lloyd's Register Quality Assurance Limited, Hiramford, Middlemarch Office Village, Siskin Drive, Coventry CV3 4FJ, United Kingdom. (Notified Body number: 0088.)

Stockholm, Sweden 2013-May-30

Ann-Cathrin Jareman

Head of QA and Regulatory Affairs